GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2006

Abbott Owns Majority of Kos Shares

  • Abbott Laboratories has purchased a majority of Kos Pharmaceuticals’ outstanding shares and intends to offer $78 per remaining share. The transaction came after Abbott’s initial offer expired on December 12, 2006, and the company decided not to extend it.

    Abbott reports that it now owns about 91.4% of Kos' outstanding common stock. In November, Abbott offered to buy Kos for $3.7 billion to expand its presence in the lipid management market, provide several on-market products, and strengthen its late-stage pipeline, says Miles D. White, chairman and CEO. The cash tender offer was for $78 per share, a 56% premium over Kos’ closing price the day before.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?